Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients

Table 2

Primary and secondary endpoints.

Primary endpoint:
Incidence of severe hepatotoxicity	10.7% (6/56 Patients)
Secondary endpoints
NNRTIs	3 cases/1203 months
	0.249 cases per 100 months of exposure
Efavirenz	2 cases/923 months
	0.217 cases per 100 months of exposure
Nevirapine	1 case/280 months
	0.357 cases per 100 months of exposure
PIs	3 cases/996 months
	0.301 cases per 100 months of exposure
Indinavir	1 case/97 months
	1.03 cases per 100 months of exposure
Nelfinavir	1 case/169 months
	0.592 cases per 100 months of exposure
Saquinavir/Ritonavir	1 case/100 months
	1.00 cases per 100 months of exposure